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Abstract 10 
This work aims to understand the properties of co-formers that form co-amorphous 11 
pharmaceutical materials and to predict co-amorphous system formation. A partial least 12 
square – discriminant analysis (PLS-DA) was performed using known co-amorphous systems 13 
described by 36 variables based on the properties of the co-former and the binding energy of 14 
the system. The PLS-DA investigated the propensity to form co-amorphous material of the 15 
active pharmaceutical ingredients: mebendazole, carvedilol, indomethacin, simvastatin, 16 
carbamazepine and furosemide in combination with 20 amino acid co-formers. The variables 17 
that were found to favour the propensity to form co-amorphous systems appear to be a 18 
2 
 
relatively large value for average molecular weight and the sum of the difference between 19 
hydrogen bond donors and hydrogen bond acceptors for both components, and a relatively 20 
small or negative value for excess enthalpy of mixing, excess enthalpy of hydrogen bonding 21 
and the difference in the Hansen parameter for hydrogen bonding of the coformer and the 22 
active pharmaceutical ingredient (API). To test the predictive power of this model, 29 23 
potential co-formers were used to form either co-amorphous or crystalline two-component 24 
materials with mebendazole. Of these 29 two-component systems, the co-amorphous nature 25 
of a total of 26 materials was correctly predicted by the model, giving a predictive hit rate of 26 
90 %. 27 
Keywords 28 
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1. Introduction 34 
A large proportion of newly discovered active pharmaceutical ingredients (APIs) display 35 
poor solubility in the gastrointestinal fluids, which is likely to decrease their bioavailability 36 
(Di et al., 2012; Kalepu and Nekkanti, 2015; Khadka et al., 2014; Savjani et al., 2012). To 37 
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improve the aqueous solubility of APIs, different formulation methods have been designed 38 
including amorphous forms, which have no long-range crystallographic order and higher 39 
internal energy compared with their respective crystalline forms (Berry and Steed, 2017; 40 
Healy et al., 2017; Khodadadi and Meesters, 2018; Williams et al., 2013). However, pure 41 
amorphous APIs are often physically unstable and can crystallise as a result of increased 42 
molecular mobility, especially when stored above their glass transition temperature or in 43 
humid environments (Kissi et al., 2018; Rams-Baron et al., 2018; Sun et al., 2012). Methods 44 
to improve the stability of amorphous APIs include the formation of amorphous solid 45 
dispersions and co-amorphous (COAM) materials (Karagianni et al., 2018; Ma and Williams, 46 
2019; Van Den Mooter, 2012; Wu et al., 2018). 47 
Amorphous solid dispersions are formed by (molecularly) dispersing an API in a (usually 48 
amorphous) polymer such as polyvinylpyrrolidone and cellulose based polymers, which act 49 
as an inactive stabilizer (Chavan et al., 2019; Nielsen et al., 2015; Vasconcelos et al., 2016). 50 
Stabilization (even above the solubility limit of the API in the polymer) is caused by the 51 
polymer increasing the glass transition temperature and forming intermolecular interactions, 52 
which in turn result in reduced molecular mobility (Baghel et al., 2016; Frank and Matzger, 53 
2018; Medarević et al., 2019). The main challenges with using amorphous solid dispersions 54 
are their often high hygroscopicity (causing increased molecular mobility of the API), and the 55 
usually large mass ratios of polymer to API (causing downstream formulation problems when 56 
high API dosages are required) (Marsac et al., 2008; Rumondor et al., 2009; Tian et al., 57 
2015). 58 
COAM systems are formed by mixing an API with a low molecular weight compound called 59 
a co-former, which is usually inactive but could also be another API (Gao et al., 2013; 60 
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Newman et al., 2018; Shayanfar and Jouyban, 2013; Shi et al., 2019). The ratio of API to co-61 
former can be relatively high which helps in the formation of high API dosage tablets (Jensen 62 
et al., 2016b; Wang et al., 2019). COAM systems are similar to co-crystals with them both 63 
containing two components, usually with one API and one co-former (Karimi-Jafari et al., 64 
2018). The difference between co-crystals and COAM systems is that co-crystals are based 65 
on a repeating three dimensional crystal lattice whereas COAM systems have no repeating 66 
units and an amorphous structure (Newman et al., 2018). The physical stability of COAM 67 
systems is usually higher than that of pure amorphous materials and COAM systems often 68 
have improved dissolution characteristics compared to pure amorphous APIs (Löbmann et 69 
al., 2013a; Löbmann et al., 2012b). COAM systems are stabilised, for example, by the 70 
formation of hydrogen bonds, π-π stacking and ionic bonds between the two compounds, as 71 
shown by infrared spectroscopy (Löbmann et al., 2012a; Löbmann et al., 2013b). Methods to 72 
produce COAM systems include co-melting, solvent evaporation and mechanochemistry 73 
(Chavan et al., 2016). Co-melting involves melting the components followed by rapid cooling 74 
to avoid nucleation and recrystallization (Hoppu et al., 2009; Knapik et al., 2015; Teja et al., 75 
2015). A key challenge in co-melting is that some of the APIs or co-formers may thermally 76 
degrade if kept at high temperatures for too long (Fan et al., 2019; Goodwin et al., 2018). 77 
Solvent evaporation involves dissolving the two components into a solvent or solvent mixture 78 
followed by rapidly evaporating the solvent to prevent nucleation and recrystallization 79 
(Ahmed Mahmoud Abdelhaleem et al., 2015; Yamamura et al., 2002). However, finding a 80 
solvent or solvent mixture which can dissolve both the co-former and the API without one 81 
component crystallising prematurely is a challenge (Mishra et al., 2018). Mechanochemistry 82 
involves using mechanical stress to reduce crystallinity and induce intimate mixing (Chieng 83 
et al., 2009; Hu et al., 2014). The conventional method used for mechanochemistry is milling. 84 
A low temperature is preferred during milling to promote the formation of an amorphous 85 
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material by keeping the mixture below the glass transition temperature of the amorphous 86 
system (Blaabjerg et al., 2017). 87 
The possible co-formers used to form COAM systems are numerous but there is no clear 88 
method of predicting whether a certain co-former will form a COAM system with a specific 89 
API. Mizoguchi et al. (2019) linked the formation of COAM systems to the mixing enthalpy 90 
and the difference in lipophilicity (Δlog P). This work used COSMOquick, a computational 91 
program which uses the Conductor like Screening Model for Real Solvents (COSMO-RS) 92 
method to derive charge density surfaces which describe each molecule and can be used to 93 
calculate interaction energies with other components (Klamt, 2018). COSMOquick can be 94 
used to screen for potential co-crystals and provides values for the Gibbs energy of mixing 95 
(ΔGmix), which determines whether mixing between potential co-crystal formers at constant 96 
temperature and pressure is spontaneous, as well as the excess enthalpy of mixing, which is 97 
the enthalpy released or absorbed upon mixing (Loschen and Klamt, 2015). Ueda et al. 98 
(2016) performed a multivariate analysis of physiochemical variables of co-formers and 99 
concluded that a range of these variables (crystallisation tendency, glass transition 100 
temperature and molecular flexibility) contributed to COAM formation; however, this study 101 
only used one API (naproxen) and a small number of co-formers (felbinac, flufenamic acid, 102 
loxoprofen, ketoprofen, indomethacin, aceclofenac, indoprofen).  103 
Meng-Lund et al. (2018) used a range of molecular descriptors to produce a PLS-DA model 104 
to predict the likelihood of success of co-amorphisation between amino acids and an API. 105 
The model used a dataset formed from 6 APIs and 20 amino acids from Kasten et al. (2016). 106 
The variables used include physical properties, Hückel theory descriptors, subdivided surface 107 
areas, atom counts, bond counts, pharmacophore feature descriptors, partial charge 108 
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descriptors, surface area, volume and shape descriptors. To test the model, one of the six 109 
APIs was left out of the model and used as a validation set. Out of the 20 systems in the 110 
validation set, 19 were correctly assigned. The model showed that polar amino acids were 111 
less likely to form COAM systems and non-polar side chains were more likely to form 112 
COAM systems. However, this model only investigated amino acid co-formers. 113 
The current study aims to develop a method to improve the selection of co-formers to 114 
formulate COAM systems. The previously reported COAM screen by Kasten et al. (2016) 115 
was used to understand which variables affect the formation of COAM systems. Variables 116 
used to describe the systems were obtained using COSMOquick to calculate properties that 117 
describe the two-component systems and Pubchem to source physico-chemical variables to 118 
describe the co-formers. The 36 variables from COSMOquick and Pubchem were used to 119 
develop a partial least squares-discriminant analysis (PLS-DA) prediction method to identify 120 
which co-formers are likely to form COAM systems. 121 
2. Materials and Methods 122 
2.1 Materials 123 
Succinic acid was purchased from Avocado Research Chemicals (Heysham, UK). Glycine 124 
(GLY) was purchased from BDH Chemicals Limited (Hull, UK). Carvedilol (CAR) was 125 
obtained from Cilpa Ltd. (Mumbai, India). L-alanine (ALA), flurbiprofen, furosemide (FUR), 126 
L-isoleucine (ILE), L-leucine (LEU), L-lysine (LYS), mebendazole (MEB) and L-tyrosine 127 
(TYR) were purchased from Flourochem (Hadfield, UK). Indomethacin (IND) was purchased 128 
from Hawkins Pharmaceutical group (Minnesota, USA). Urea was purchased from Lancaster 129 
Synthesis (Lancaster, UK). Maleic acid was purchased from M&B Chemicals (London, UK). 130 
3-aminobenzoic acid, 4-aminobenzoic acid, 4-aminosalicylic acid, 5-aminosalicylic acid, L-131 
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arginine (ARG), ascorbic acid, L-asparagine (ASN), L-aspartic acid (ASP), 4,4’-bipyridine, 132 
caffeine, catechol, L-cysteine (CYS), 2,4 dihydroxybenzoic acid, 3,5-dihydroxybenzoic acid, 133 
fumaric acid, gallic acid, L-glutamine (GLN), L-glutamic acid (GLU), glycolic acid, L-134 
histidine (HIS), imidazole, isonicotinamide, ketoprofen, L-methionine (MET), nicotinamide, 135 
oxalic acid, L-phenylalanine (PHE), phenazine, piperazine, piracetam, L-proline (PRO), 136 
pyrogallol, salicylic acid, L-serine (SER), tartaric acid, theophylline, L-threonine (THR), L-137 
tryptophan (TRP) and L-valine (VAL) were purchased from Sigma Aldrich (Missouri, USA). 138 
2.2 Mebendazole co-former screening 139 
Ball milling was used to screen for potential COAM systems. A 1:1 molar ratio of API and 140 
co-former (total 100 mg), was placed into a 5 mL milling jar and premixed at a frequency of 141 
30 Hz for 5 minutes without a mixing ball to homogenize the material. A stainless-steel ball 142 
with a diameter of 5 mm was added and the mixture was milled at 30 Hz for 60 min. The 143 
milling time of 60 min was selected due to it matching the original study the model was 144 
produced from (Kasten et al., 2016). Milling was performed using a Mixer mill MM200, 145 
vibrational ball mill, from Retsch GmbH & Co. (Haan, Germany). The mixtures were 146 
analysed by XRPD to assess crystallinity (see below). 147 
2.3 Film casting mebendazole – gallic acid 148 
A 1:1 molar ratio of mebendazole to gallic acid (63.5 mg: 36.5 mg), was dissolved in a 149 
minimum amount of formic acid (approx. 10 mL). The solution was cast onto a petri dish and 150 
the formic acid was left to evaporate. Once the mixture was dry, it was analysed by XRPD 151 
(see below). 152 
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2.4 X-ray powder diffraction (XRPD) 153 
XRPD measurements were performed using a Bruker D8 X-ray diffractometer (Billerica, 154 
Massachusetts) with CuKα radiation (1.54187 Å), and acceleration voltage and current of 40 155 
kV and 40 mA, respectively. The samples were scanned in reflectance mode between 2° and 156 
35° 2θ with a scan rate of 0.067335° 2θ/s and a step size of 0.026°. 157 
2.5 COSMOquick calculations 158 
COSMOquick version 1.7 (COSMOlogic GmbH & Co. KG, Leverkusen, Germany) was used 159 
to calculate the Gibbs energy of mixing (ΔGmix), excess enthalpy of mixing (ΔHmix) and excess 160 
enthalpy of hydrogen bonding (ΔHhb), of the two-component system. For each component the 161 
following variables were calculated and displayed in Table 1: the number of Rotatable bonds; 162 
rotbsdmod, a general molecular flexibility parameter; M2, M3, M4, M5 and M6, the different 163 
order sigma moments; the dielectric energy; the molecular COSMO volume; Macc1, Macc2, 164 
Macc3 and Macc4, the different order sigma acceptor moments; Mdon1, Mdon2, Mdon3 and 165 
Mdon4, the different order sigma donor moments; avratio, the surface-volume ratio based on 166 
COSMO; ovality, the ratio of the molecular COSMO area to the area of a sphere with the 167 
same volume as the molecule; µ, the pseudo chemical potential of the pure solute; δd, the 168 
Hansen parameter for dispersion; δp, the Hansen parameter for permanent dipole-dipole 169 
interaction; δh, the Hansen parameter for hydrogen bonding. The difference between the API 170 
and co-former values were calculated and used as the variables in the PLS-DA. 171 
Table 1: The definitions of all the variables used to find the PLS-DA model. 172 
Variable Definition 
ΔGmix Gibbs energy of mixing. 
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ΔHhb Excess enthalpy of hydrogen bonding. 
ΔHmix Excess enthalpy of mixing.  
Δlog P 
The difference between the log of the octanol/water partition coefficient 
of the API and the co-former 
AV. log P 
The average value of the log of the octanol/water partition coefficient of 
the API and the co-former 
ΣHBCself 
The sum of the difference of hydrogen bond donors to hydrogen bond 
acceptors for the individual components, for both the API and co-
former. To represent the hydrogen bonding present in the individual 
components. 
ΣHBCAPI-COF 
The sum of the difference of hydrogen bond donors to hydrogen bond 
acceptors for the mixed components, for both the API and co-former. 
To represent the hydrogen bonding between the two components. 
AV. TM The average melting point of the two components.  
Δ TM The difference of the melting point of the co-former and the API. 
AV. MW The average molecular weight of the API and the co-former. 
Δ MW The difference of the molecular weights of the API and the co-former. 
AV. TPSA 
The average topological polar surface area of the API and the co-
former. 
ΔTPSA 
The difference between the topological polar surface area of the API 
and the co-former. 
Δrotatable 
bonds 
The difference between the number of rotatable bonds of the co-former 
and the API. 
Δrotbsdmod 
The difference between the general molecular flexibility parameter of 
the co-former and the API. 
ΔM2 
The difference between the second order sigma moments of the co-
former and the API. 
ΔM3 
The difference between the third order sigma moments of the co-
former and the API. 
ΔM4 
The difference between the fourth order sigma moments of the co-
former and the API. 
ΔM5 
The difference between the fifth order sigma moments of the co-former 




The difference between the sixth order sigma moments of the co-
former and the API. 
ΔDielectric 
energy 
The difference between the number of rotatable bonds of the co-former 
and the API. 
Δvolume 
The difference between the dielectric energy of the co-former and the 
API. 
ΔMacc1 
The difference between the first order sigma acceptor moments of the 
co-former and the API. 
ΔMacc2 
The difference between the second order sigma acceptor moments of 
the co-former and the API. 
ΔMacc3 
The difference between the third order sigma acceptor moments of the 
co-former and the API. 
ΔMacc4 
The difference between the fourth order sigma acceptor moments of 
the co-former and the API. 
ΔMdon1 
The difference between the first order sigma donor moments of the co-
former and the API. 
ΔMdon2 
The difference between the second order sigma donor moments of the 
co-former and the API. 
ΔMdon3 
The difference between the third order sigma donor moments of the co-
former and the API. 
ΔMdon4 
The difference between the fourth order sigma donor moments of the 
co-former and the API. 
Δavratio 
The difference between the surface-volume ratio based on COSMO of 
the co-former and the API. 
Δovality 
The difference between co-former and the API of the ratio of the 
molecular COSMO area to the area of a sphere with the same volume 
as the molecule. 
Δµ 
The difference between the pseudo chemical potential of the pure 
solute of the API and the co-former. 
Δ(δd) 
The difference between the Hansen parameter for dispersion in MPa0.5 
of the API and the co-former. 
Δ(δp) 
The difference between the Hansen parameter for permanent dipole-




The difference between the Hansen parameter for hydrogen bonding in 
MPa0.5 of the API and the co-former. 
 173 
2. 6 Partial least squares – discriminant analysis 174 
Partial least squares – discriminant analysis  (PLS-DA) was performed using SIMCA V.16 175 
(Umetrics, Umeå, Sweden) to plot 36 variables for each combination of API and co-former 176 
(Brereton and Lloyd, 2014; Sadeghi-Bazargani et al., 2010). The 36 different variables 177 
plotted were ΔGmix, ΔHmix, ΔHhb, Δlog P, AV.log P, ΣHBCself, ΣHBCAPI-COF, AV.TM, ΔTM, 178 
AV.MW, ΔMW, AV.TPSA, ΔTPSA, ΔRotatable bonds, Δrotbsdmod, ΔM2, ΔM3, ΔM4, ΔM5, 179 
ΔM6, ΔDielectric energy, Δvolume, ΔMacc1, ΔMacc2, ΔMacc3, ΔMacc4, ΔMdon1, ΔMdon2, 180 
ΔMdon3, ΔMdon4, Δavratio, Δovality, Δµ, Δ(δd), Δ(δp) and Δ(δh) (Table 1). The data was 181 
scaled using unit variance. Each system was assigned as either COAM or not COAM (any 182 
crystalline material present) as determined by Kasten et al. (2016) based on analysing the 183 
mixture by XRPD after ball milling for 60 minutes. The PLS-DA was fitted using two latent 184 
variables and all 36 variables. The quality of the model was assessed using an internal cross-185 
validation procedure which involved leaving one out using seven cross-validation groups. 186 
The prediction ability of the model was assessed by checking the predicted values of COAM 187 
formation of the 120 API-amino acid dataset and comparing the values with the experimental 188 
results. The prediction gives a predicted numerical value with a value closer to one being 189 
COAM and a value closer to zero being not COAM. The prediction of the model was also 190 
assessed by using a dataset of 29 co-formers paired with mebendazole. The predicted values 191 
for the mebendazole-co-former dataset were compared with the experimental values to 192 
determine the prediction ability. 193 
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Variable selection was used to reduce the number of variables from 36 to 7 based on 194 
optimising the number of correctly predicted samples for the API-amino acid dataset. The 195 
final model was produced in JMP Pro 15 to view the equation used to assign the COAM 196 
value (Equation 1) (JMP, Version Pro 15. 1989-2020). 197 
Predicted COAM value198 
= (−0.123 × 𝛥𝐻ℎ𝑏) + (−0.136 × 𝛥𝐻𝑚𝑖𝑥) + (−0.00350 × 𝛴𝐻𝐵𝐶𝑠𝑒𝑙𝑓)199 
+ (0.00297 × 𝐴𝑉. 𝑀𝑊) + (−0.00176 × 𝛥𝑇𝑃𝑆𝐴) + (0.0105 × 𝛥µ)200 
+ (−0.0441 × 𝛥(𝛿ℎ)) + (−0.204)  201 
Equation 1: The equation to describe the relation of the seven key variables to the predicted 202 
COAM value. All numbers have been rounded to 3 significant figures. A value closer to one 203 
indicates the system should be COAM and a value closer to zero indicates it should not be 204 
COAM. 205 
3. Results and Discussion 206 
3.1 Correlation of ΔHmix and Δlog P with co-amorphisation 207 
The COAM systems used in this screen were experimentally identified by Kasten et al. 208 
(2016) and the responses listed in supplementary materials Table S1 indicate which systems 209 
formed COAM materials after 60 min of ball milling. The APIs used were carvedilol (CAR), 210 
furosemide (FUR), indomethacin (IND) simvastatin (SIM), carbamazepine (CBZ) and 211 
mebendazole (MEB). Previous research on theoretical descriptors for the prediction of the 212 
formation of a COAM system identified two indicators (ΔHmix and Δlog P) using a 213 
combination of APIs with other APIs or sugars to screen for COAM systems using 214 
differential scanning calorimetry (Mizoguchi et al., 2019). The ΔHmix was calculated using 215 
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COSMOquick and the Δlog P was sourced from Pubchem; it was found that COAM systems 216 
form with a Δlog P below 6 and a negative ΔHmix and a clear divide between the COAM 217 
systems and the crystalline systems was observed. When the ΔHmix and Δlog P for the 218 
API/amino acids systems tested by Kasten et al. (2016) were plotted against each other the 219 
same clear divide was not evident (Figure 1). The data indicates that COAM materials tend to 220 
form in systems with a lower value of Δlog P and a negative ΔHmix. However, many 221 
combinations break these trends; a few COAM systems form with a Δlog P above 6 and 222 
many systems with a Δlog P below 6 remain crystalline. Furthermore, COAM systems form 223 
with positive values of ΔHmix. To further assess the prediction ability for COAM formation of 224 
the two variables a range of 29 different co-formers (supplementary materials Table S2) were 225 
paired with mebendazole and analysed using the two variables. The 29 different co-formers 226 
were then ball milled with mebendazole to determine whether they formed COAM mixtures 227 
and the results were compared with the predicted trends. Figure 2 shows that all the systems 228 
including COAM and not COAM have a Δlog P below 6 suggesting Δlog P is not a good 229 
predictor of COAM material formation. Figure 2 also shows that the majority of the 29 230 
systems have negative values of ΔHmix but not all the systems are COAM and there is no clear 231 
divide between COAM and not COAM systems. Using these two variables to predict the 232 
formation of co-amorphous API-co-former systems was insufficient suggesting that more 233 




Figure 1. Relationship between the formation of COAM systems from Kasten et al. (2016), 236 
ΔHmix and Δlog P. Green markers indicate COAM systems were formed and red markers 237 
indicate not COAM systems. The red dotted line is the expected boundary line between 238 





Figure 2. Relationship between the formation of COAM systems of mebendazole with 29 co-242 
formers, ΔHmix and Δlog P. Green markers indicate COAM systems were formed and red 243 
markers indicate not COAM systems were formed. The red dotted line is the expected 244 
boundary line between COAM and not COAM systems based on previous research by 245 
Mizoguchi et al. (2019). Abbreviations of the coformers are as follows: 2,4-dihydroxybenzoic 246 
acid (2,4-DHBA), 3,5-dihydroxybenzoic acid (3,5-DHBA), 3-aminobenzoic acid (3-ABA), 247 
4,4’-bipryidine (BIPY), 4-aminobenzoic (4-ABA), 4-aminosalicylic acid (4-AS), 5-248 
aminosalicylic acid (5-AS), ascorbic acid (ASCA), caffeine (CAF), catechol (CATEC), 249 
flurbiprofen (FLURB), fumaric acid (FUMA), gallic acid (GALA), glycolic acid (GLYA), 250 
imidazole (IMID), isonicotinamide (INICO), ketoprofen (KETO), maleic acid (MALA), 251 
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nicotinamide (NICO), oxalic acid (OXA), phenazine (PHENA), piperazine (PIP), piracetam 252 
(PIRA), pyrogallol (PYROG), salicylic acid (SALCA), succinic acid (SUCA), tartaric acid 253 
(TARTA), theophylline (THEO), and urea (UREA). 254 
3.2 PLS-DA 255 
To improve the prediction of COAM systems, 34 additional variables were selected to 256 
describe the properties and interactions of the two components and combined with ΔHmix and 257 
Δlog P. These 36 variables (Table 1) were used to produce a PLS-DA model to understand 258 
which variables affect COAM system formation. Variable selection was then used to reduce 259 
the initial 36 variables to seven key variables. Variable selection was performed by removing 260 
variables one after the other and checking the effect on the prediction ability of the model for 261 
the API amino acid data set; if the variable had no effect it was removed and if the prediction 262 
ability was reduced it was retained. The variables selected describe differences between the 263 
API and co-former allowing the model to be applied to systems where the API and co-former 264 
cannot be easily defined, such as systems formed from two APIs. The final PLS-DA model 265 
includes the seven descriptors (Table 1): ΔHhb, ΔHmix, ΣHBCself, AV. MW, ΔTPSA, Δµ and 266 
Δ(δh). The goodness of fit is R2Y = 33.0 %, R2X = 47.8 % and the goodness of prediction is 267 
Q2 = 29.0 % based on two latent variables. Latent variables are variables which cannot be 268 
measured and are inferred from mathematical models. 269 
3.3 Model 270 
The score scatter plot of the PLS-DA model for the API amino acid systems (Figure 3) shows 271 
a division between COAM and not COAM systems with COAM systems appearing more in 272 
the top right quadrant. The dotted line in Figure 3 shows the predicted separation for 273 
visualization purposes between the COAM and not COAM systems. The not COAM systems 274 
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occur on the left of the plot and mainly in the bottom left quadrant. Equation 1 shows the 275 
relationship of each variable to the overall prediction. 276 
 277 
Figure 3. PLS-DA score scatter plot of latent variables (LV) 1 and 2. The red markers 278 
indicate not COAM systems and the green markers show COAM systems. The APIs are 279 
displayed with different markers with carvedilol (CAR) displayed as an X, carbamazepine 280 
(CBZ) as a triangle, furosemide (FUR) as a hollow square, indomethacin (IND) as a cross, 281 
mebendazole (MEB) as a circle and simvastatin (SIM) as a hollow diamond. The dashed blue 282 
line shows the predicted separation between COAM and Not COAM systems for 283 
visualization purposes. 284 
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The loading plot (Figure 4) shows how each variable is related to COAM formation. The 285 
variables closest to the COAM response are linked to COAM formation and the variables 286 
closest to the not COAM response are linked to not COAM formation. The two variables 287 
ΔTPSA and Δµ are located roughly in the middle between the COAM and not COAM point 288 
and therefore, do not appear to influence the COAM formation to a strong degree, however, 289 
when they are removed the prediction ability of the model is reduced. The variables related to 290 
COAM formation, therefore, appear to be a relatively large value of AV. MW and ΣHBCself, 291 
and a relatively small or negative value of ΔHmix, ΔHhb, and Δ(δh). A large AV.MW seems to 292 
correlate with COAM formation possibly due to slower diffusion which would inhibit 293 
recrystallization. A large value of ΣHBCself correlates with COAM formation, which is 294 
expected due to molecules that do not have a similar number of hydrogen bond donor atoms 295 
and hydrogen bond acceptor atoms are unlikely to form as strong crystal structures and may 296 
be more likely to interact with the other component (Corpinot and Bučar, 2019). A negative 297 
value of ΔHmix favours COAM formation, as expected since negative values indicate that the 298 
mixed system has a lower free energy state due to stronger attractive forces between the 299 
mixed molecules compared to the individual component interaction. A negative value ΔHhb 300 
also favours COAM formation which is due to stronger hydrogen bonding between the mixed 301 
molecules when compared with the individual components. A small Δ(δh) seems to favour 302 
COAM formation suggesting molecules with similar hydrogen-bonding potential are more 303 




Figure 4. PLS-DA loading weights scatter plot of the latent variables (LV) 1 and 2. The 306 
responses are shown with orange circles and the variables with blue circles. The responses 307 
show how the two groups are related to the variables. 308 
The score plot (Figure 3) shows the two clusters of COAM and not COAM samples overlap 309 
to some degree. Overall, the misclassification table (which shows if the prediction matches 310 
the experimental result) (Table 2) of the 120 API – amino acid dataset shows that 81 % of the 311 
data points are correctly placed, suggesting the PLS-DA model is successful at modelling the 312 
amino acid data. Out of the 23 misplaced systems, 18 are close to the separation line and five 313 
are very far from the separation line, these five systems are MEB with LYS, LEU and ILE, 314 
SIM with LYS, and IND with HIS. The MEB with LYS, LEU and ILE and SIM with LYS 315 
systems were shown by Kasten et al. (2019) to have a low stability and underwent 316 
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crystallisation within a few weeks suggesting the model helps identify stable COAM systems. 317 
The fifth system furthest from the separation line was IND with HIS which was not COAM 318 
by milling, however a study by Jensen et al. (2016a) showed IND with HIS system was co-319 
amorphous when spray dried, this suggest the model could be valid for other co-amorphous 320 
production methods.  321 
Table 2. Misclassification table showing the percentage of correctly assigned observations of 322 
the 120 API-amino acid combinations. Fisher’s probability of 4.7 x 10-8. 323 






84 90.48% 76 8 
COAM 36 58.33% 15 21 
Total 120 80.83% 91 29 
3.5 Prediction of co-amorphous formation by mebendazole with 29 co-formers 324 
To test the applicability of the PLS-DA model (Figure 3, Figure 4) to other non-amino acid 325 
systems, a new dataset of 29 different co-formers with mebendazole was used. Mebendazole 326 
was selected due to it forming a range of both of COAM and not COAM systems with the 327 
amino acids; therefore, it was expected to form a range of both co-amorphous and not COAM 328 
systems with other co-formers. The 29 co-formers were selected on the basis of being small 329 
molecules capable of forming a range of different hydrogen-bonding motifs. The model was 330 
applied to predict the classification of the mebendazole co-former mixtures and the prediction 331 
was compared to experimental data. The misclassification table (Table 3) shows that overall, 332 
86 % of the samples were predicted correctly and only four of 29 mixtures were predicted 333 
incorrectly. The score plot of the predicted scores (Figure 5) shows a clear divide between 334 
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systems that were COAM and systems that were not COAM, with only a slight overlap of the 335 
two clusters. 336 
 337 
Figure 5. Score scatter plot of the predicted scores for the mebendazole-co-former 338 
combinations. COAM samples are shown in green, not COAM samples are shown in red. 339 
The hollow circles indicate samples which have been predicted incorrectly. The blue dashed 340 
line shows the predicted separation line for visualization purposes. 341 
Table 3. Misclassification table showing the percentage of correctly assigned observation of 342 
the 29 MEB-co-former combinations. Fisher’s probability of 1.8 x 10-4. 343 








17 88.24% 15 2 
COAM 12 83.33% 2 10 
Total 29 86.21% 17 12 
The four samples that were predicted incorrectly were MEB combinations with theophylline, 344 
3-aminobenzoic acid, maleic acid and gallic acid, with predicted COAM values of 0.43, 0.52, 345 
0.40 and 0.86, respectively. The COAM values indicate how close the prediction is to 346 
assigning the system as COAM or not COAM with a value above 0.5 indicating COAM and 347 
a value below 0.5 indicating not COAM. Three of the samples had COAM values close to the 348 
cross over point at 0.5, suggesting they were close to being predicted correctly and may have 349 
been misplaced by one or two variables having extreme values. Theophylline appears to be 350 
incorrectly predicted due to the system having a relatively high value of ΔHmix and ΔHhb 351 
compared to the other systems. 3-aminobenzoic acid was misplaced due to a relatively 352 
small/negative ΔHmix and ΔHhb and a small Δ(δh). Maleic acid is misplaced due to a small 353 
MW. The gallic acid system is the furthest away from the crossover line between COAM and 354 
not COAM systems, suggesting it should be COAM. The mebendazole gallic acid system 355 
was investigated using film casting which resulted in a COAM system, this suggests the 356 
model is not limited to system produced by only ball milling. Film casting was selected 357 
because it involves a thermodynamic pathway with the initial solution containing no 358 
crystalline material compared to ball milling which is a kinetic pathway involving the 359 
disruption of the crystal lattice (Karagianni et al., 2018). Therefore, film casting is likely to 360 
help the formation of a co-amorphous system if the initial crystalline material is too stable to 361 
be broken down by ball milling. With the mebendazole gallic acid system now being classed 362 
as COAM the misclassification table improves and the correct prediction percentage is now 363 
90 % (Table 4). The model now shows an even clearer divide between the two clusters with 364 
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only a few outliers which are close to the cross over line. Film casting was not used to test 365 
other systems due to other co-amorphous formation methods usually producing a similar 366 
result (Karmwar et al., 2011; Lim et al., 2016).  367 
Table 4: Misclassification table showing the percentage of correctly assigned observations of 368 
the 29 MEB-co-former combinations after gallic acid was confirmed as being COAM by film 369 
casting. Fisher’s probability of 2.4 x 10-5. 370 






16 93.75% 15 1 
COAM 13 84.62% 2 11 
Total 29 89.66% 17 12 
 371 
4. Conclusion 372 
Known COAM systems formed with APIs and amino acid co-formers were analysed to 373 
identify properties of the co-former that correlate with COAM material formation (Kasten et 374 
al., 2016). A range of 36 variables was used to describe the properties of the API-amino acid 375 
systems and a multivariate PLS-DA was used to create a prediction model. The initial 36 376 
variables were reduced to seven variables including ΔHhb, ΔHmix, ΣHBCself, AV. MW, ΔTPSA, 377 
Δµ and Δ(δh). The model predicts 81 % of the API-amino acid systems correctly. The model 378 
was tested using a dataset of mebendazole with 29 different co-formers and 90 % of the 379 
systems were correctly predicted. Overall, the model can predict the potential COAM 380 
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formation of a range of co-formers significantly expanding its applicability beyond the 381 
relatively limited set of amino acid co-formers. 382 
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